ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Dmitrovsky Named Provost at MD Anderson; Paulsen Leaves To Chair Duke Radiology

April 12, 2013

NIH “RFA Game” Defeats Purpose Of OAM, Advisor Says

September 30, 1994

DeVita Says Payline Compression Leading to More Decisions By Staff On Funding

June 28, 1985

NCI Director Halts STELLAR Trial, Seeks “Brilliant Ideas” For Breast Cancer Prevention.

March 2, 2007

In Brief; Burkitt, Epstein Will Divide Bristol-Myers Award; “Italian Nobel” Won By Columbia’s Sol Spiegelman

March 26, 1982

Cancer Letter Closes Out 1983, 10th Year

December 16, 1983